Physician profile
William D Daniel
NPI 1497851786
$3,599.02
in general payments reported to CMS, 2019-2025
34 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $370 · 2021: $613 · 2022: $793 · 2023: $573 · 2024: $491 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.84 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $494.25 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $352.40 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $274.88 | 2019-2023 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $200.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $170.68 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.76 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $156.01 | 2019-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $141.50 | 2019-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $103.38 | 2021-2024 | Gvoke Hypopen |
| Amgen INC. | $94.70 | 2021-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $91.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $84.56 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $65.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.30 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $47.21 | 2022 | |
| Boston Scientific Corporation | $46.80 | 2020 | |
| Dexcom, INC. | $44.14 | 2021-2022 | |
| Amarin Pharma, INC. | $35.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.40 | 2020-2021 | |
| Allergan, INC. | $28.46 | 2020 | |
| Esperion Therapeutics, INC. | $27.42 | 2021 | |
| Abbott Laboratories | $26.95 | 2020-2021 | |
| Axsome Therapeutics, INC. | $25.09 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $25.01 | 2021 | |
| Sumitomo Pharma America, INC. | $24.31 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $21.50 | 2024 | Vyepti |
| Medtronic Minimed, INC. | $16.59 | 2020 | |
| Inspire Medical Systems, INC. | $16.32 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.13 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.93 | 2020 | |
| Mylan Specialty L.P. | $14.83 | 2022 | |
| Exact Sciences Corporation | $13.94 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.